论文部分内容阅读
目的：观察尼莫地平注射液早期应用与巨大脑血肿死亡率之间的关系。方法：将４３例巨大脑血肿病人随机分为尼莫地平组２０例和对照组２３例。２组均于发病６小时内接受治疗，对照组用脱水降颅压、活化脑细胞及降压等常规疗法，尼莫地平组在常规疗法基础上加用尼莫地平注射液５０ｍｌ（含１０ｍｇ），静脉滴注，ｑｄ×７ｄ。结果：尼莫地平组死亡率明显低于对照组（Ｐ＜０．０５）。结论：尼莫地平注射液早期应用可明显减低巨大脑血肿的死亡率
Objective: To observe the relationship between the early application of nimodipine injection and the mortality rate of giant cerebral hematoma. Methods: Forty-three patients with giant brain hematoma were randomly divided into nimodipine group (n = 20) and control group (n = 23). 2 groups were treated within 6 hours of onset, the control group with dehydration reduced intracranial pressure, activation of brain cells and blood pressure and other conventional therapy, nimodipine group based on conventional therapy plus nimodipine injection 50ml (containing 10mg) , Intravenous drip, qd × 7d. Results: The mortality of nimodipine group was significantly lower than that of control group (P <0.05). Conclusion: The early application of nimodipine injection can significantly reduce the mortality rate of giant brain hematoma